The Mazor Robotics’ (MZOR) “Hold” Rating Reiterated at Barclays PLC

The Mazor Robotics’ (MZOR) “Hold” Rating Reiterated at Barclays PLC

Barclays PLC restated their hold rating on shares of Mazor Robotics Ltd. (NASDAQ:MZOR) in a report released on Wednesday morning. Barclays PLC currently has a $34.00 price target on the medical instruments supplier’s stock.

A number of other analysts also recently weighed in on the stock. Needham & Company LLC reaffirmed a hold rating on shares of Mazor Robotics in a report on Wednesday, August 30th. Ladenburg Thalmann Financial Services set a $54.00 price target on shares of Mazor Robotics and gave the stock a buy rating in a report on Wednesday, August 30th. Finally, Zacks Investment Research downgraded shares of Mazor Robotics from a hold rating to a sell rating in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company’s stock. Mazor Robotics currently has a consensus rating of Hold and a consensus price target of $37.67.

Shares of Mazor Robotics (NASDAQ:MZOR) opened at 54.07 on Wednesday. The firm’s market cap is $1.30 billion. Mazor Robotics has a 12-month low of $20.19 and a 12-month high of $55.66. The stock’s 50 day moving average is $48.11 and its 200 day moving average is $39.48.

Mazor Robotics (NASDAQ:MZOR) last issued its quarterly earnings results on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.09. Mazor Robotics had a negative net margin of 37.66% and a negative return on equity of 28.51%. The company had revenue of $15.46 million during the quarter, compared to the consensus estimate of $15.38 million. During the same quarter in the prior year, the firm posted ($0.09) EPS. The firm’s quarterly revenue was up 86.7% on a year-over-year basis. Equities analysts expect that Mazor Robotics will post ($0.77) earnings per share for the current year.

A number of large investors have recently modified their holdings of MZOR. Wells Fargo & Company MN lifted its stake in Mazor Robotics by 46.3% in the 1st quarter. Wells Fargo & Company MN now owns 40,958 shares of the medical instruments supplier’s stock valued at $1,220,000 after purchasing an additional 12,959 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Mazor Robotics by 398.5% in the 1st quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock valued at $208,000 after purchasing an additional 5,579 shares during the last quarter. Credit Agricole S A bought a new position in Mazor Robotics in the 1st quarter valued at approximately $3,929,000. Menta Capital LLC bought a new position in Mazor Robotics in the 1st quarter valued at approximately $815,000. Finally, UBS Group AG lifted its stake in Mazor Robotics by 2.4% in the 1st quarter. UBS Group AG now owns 99,954 shares of the medical instruments supplier’s stock valued at $2,976,000 after purchasing an additional 2,379 shares during the last quarter. 25.92% of the stock is owned by institutional investors and hedge funds.

Mazor Robotics Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Related posts

Leave a Comment